| Budget Amount *help |
¥74,500,000 (Direct Cost: ¥74,500,000)
Fiscal Year 2009: ¥14,900,000 (Direct Cost: ¥14,900,000)
Fiscal Year 2008: ¥14,900,000 (Direct Cost: ¥14,900,000)
Fiscal Year 2007: ¥14,900,000 (Direct Cost: ¥14,900,000)
Fiscal Year 2006: ¥14,900,000 (Direct Cost: ¥14,900,000)
Fiscal Year 2005: ¥14,900,000 (Direct Cost: ¥14,900,000)
|
|---|
| Research Abstract |
By characterizing the molecular mechanism of tumor cell recognition and lysis by cytotoxic T cells and natural killer cells, we have developed the anti-DR5 therapy which mimics it. We have also developed novel strategies to augment anti-tumor immunity by using antibodies activating the immuno-stimulatory pathways (such as CD40, CD27, and 4-1BB) and those blocking the immuno-suppressive pathways (such as CTLA-4, PD-1, and B7-H3).
|
